US$ 23.76
side effects of glp-1 drugs GI Adverse Glucagon-Like Peptide-1 Receptor Agonists Gastrointestinal side effects of anti-obesity
Description
In comparison to sitagliptin, semaglutide has been shown to significantly reduce the 12-month risk of cognitive deficits, dementia, and epilepsy.[63] In PCOS, a meta-analysis indicated that exenatide and liraglutide exhibit stronger effects on insulin sensitivity and BMI reduction than metformin.[71] A 24-week study found that exenatide led to a significantly higher rate of spontaneous pregnancies and more regular menstrual cycles compared to metformin.[72] Although rapid weight loss in some contexts is associated with an increased risk of frailty fractures, GLP-1RAs may mitigate this effect.[73, 74] Both exenatide and dulaglutide were found to increase bone mineral density, while lixisenatide and liraglutide were associated with a reduced risk of fractures, suggesting differential effects of GLP-1RAs on bone metabolism.[74] OTHER CONSIDERATIONS Side effects and adverse events related to GLP1-RAs While GLP-1RAs are credited with a growing list of health benefits, they have also been associated with a wide variety of adverse effects that may vary among agents.[6, 21] Common side effects include nausea, vomiting, diarrhea, mild tachycardia, and injection site reactions.[75] A pooled analysis of 33 clinical trials (n=13,548) found an increased risk of treatment discontinuation due to gastrointestinal effects such as nausea and vomiting.[6] Potential adverse events include pancreatitis, cholelithiasis, and dehydration.[76] Rodent studies and one observational study in humans have raised concerns about GLP-1RAs impact on thyroid cancer risk

Appetite returns because the medication stops slowing down digestion and stops raising hormones," she shares

A-42 aggregates and combines to Ca 2+ channels and AMPA (-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors, to which the neurotransmitter glutamate binds, so A is the most neurotoxic form (3, 31)

The higher the dose of the GLP-1 agonist, the more extreme the effects. In simpler terms, these medications can help decrease your desire to eat

This commonality raises the question: Could GLP-1 agonists be helpful as additional therapies for IBD

10.1056/NEJMoa1307684
